Ningbo Shentai Bio was awarded “Outstanding Incubated Enterprise of 2024.”
Sep 30,2025
In September 2025, Ningbo Syntame Biotech Co.,Ltd was successfully recognized as the "Outstanding Incubated Enterprise of 2024" in the annual selection organized by the Science and Technology Bureau of Yinzhou District, Ningbo. This honor not only fully affirms the company's technological capabilities and growth speed but also highlights its commercialization ability and market value in the pharmaceutical field.
As a technology enterprise focused on pharmaceutical research and development, the company pursues the development strategy of "based on technology, creating technology." Leveraging its core proprietary technologies, the company continuously promotes product development and the transformation of research results, gradually building a complete value chain from R&D to industrialization. During the incubation period, the company not only achieved multiple technological breakthroughs but also demonstrated strong momentum in business models, customer cooperation, and market expansion.
Looking ahead, the company will take this honor as an opportunity to further integrate technology, capital, and market resources, strengthen brand building and business layout, provide customers with higher-quality products and solutions, and inject new vitality into industry advancement and regional economic development.
Shentai Exhibition Tour 2025
CPHI South East Asia 2025 comes to a successful conclusion | SYNTAME opens a new chapter in the Southeast Asian market
CPHI China 2025 ended successfully | Syntame talks with customers around the world about new opportunities for cooperation
The company team made a stunning appearance at the 22nd World Pharmaceutical Raw Materials China Exhibition (CPHI) at the Shanghai New International Expo Centre.
The company's sales team successfully participated in the 21st World Pharmaceutical Raw Materials China Exhibition (CPHI) at the Shanghai New International Expo Centre.
